Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216604328> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W3216604328 endingPage "vi134" @default.
- W3216604328 startingPage "vi134" @default.
- W3216604328 abstract "Abstract BACKGROUND The REGOMA phase 2 trial showed an encouraging overall survival benefit of the multikinase inhibitor regorafenib in glioblastoma patients at first progression. We used O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for the early assessment of response to regorafenib in patients with progressive glioma in an advanced disease stage. METHODS Thirty patients with progressive glioma were treated according to the REGOMA trial and prospectively followed. FET PET and MRI were performed at baseline and after the second cycle of regorafenib. Static PET parameters such as maximum and mean tumor-to-brain ratios (TBRmax, TBRmean) and metabolic tumor volumes (MTV) were calculated. Threshold values of FET PET parameters to predict a response were established by ROC analyses using an overall survival of ≥ 6 months as reference. The predictive value of FET PET parameters and their changes concerning overall survival was subsequently evaluated using the Kaplan-Meier test. MRI changes were evaluated according to the RANO criteria. RESULTS Up to now, 18 of 30 patients (glioblastoma, 83%; age range, 24-71 years) were eligible for data evaluation. The median number of tumor relapses before regorafenib was 2 (range, 1-4). During regorafenib (median cycles, 4; range, 2-9 cycles), CTCAE grade 3 or 4 side effects occurred in 56% and 11%, respectively. The median overall survival was 6 months (range, 3-18 months). After two cycles of regorafenib, a TBRmean reduction of 13% predicted a significantly longer overall survival (12 vs. 6 months; P=0.034). In contrast, MRI changes evaluated according to RANO criteria (i.e., Stable Disease or Partial Response vs. Progressive Disease) were not predictive (11 vs. 8 months; P=0.644). CONCLUSION Data suggest that amino acid PET using the tracer FET may be clinically valuable for identifying responders to regorafenib early after treatment initiation." @default.
- W3216604328 created "2021-12-06" @default.
- W3216604328 creator A5030332648 @default.
- W3216604328 creator A5031985321 @default.
- W3216604328 creator A5036157197 @default.
- W3216604328 creator A5041041270 @default.
- W3216604328 creator A5048404962 @default.
- W3216604328 creator A5068493621 @default.
- W3216604328 creator A5068510584 @default.
- W3216604328 creator A5075153407 @default.
- W3216604328 creator A5080394149 @default.
- W3216604328 creator A5090607268 @default.
- W3216604328 creator A5091809961 @default.
- W3216604328 date "2021-11-02" @default.
- W3216604328 modified "2023-09-27" @default.
- W3216604328 title "NIMG-27. REGORAFENIB RESPONSE ASSESSMENT USING FET PET IN PATIENTS WITH PROGRESSIVE GLIOMA" @default.
- W3216604328 doi "https://doi.org/10.1093/neuonc/noab196.527" @default.
- W3216604328 hasPublicationYear "2021" @default.
- W3216604328 type Work @default.
- W3216604328 sameAs 3216604328 @default.
- W3216604328 citedByCount "0" @default.
- W3216604328 crossrefType "journal-article" @default.
- W3216604328 hasAuthorship W3216604328A5030332648 @default.
- W3216604328 hasAuthorship W3216604328A5031985321 @default.
- W3216604328 hasAuthorship W3216604328A5036157197 @default.
- W3216604328 hasAuthorship W3216604328A5041041270 @default.
- W3216604328 hasAuthorship W3216604328A5048404962 @default.
- W3216604328 hasAuthorship W3216604328A5068493621 @default.
- W3216604328 hasAuthorship W3216604328A5068510584 @default.
- W3216604328 hasAuthorship W3216604328A5075153407 @default.
- W3216604328 hasAuthorship W3216604328A5080394149 @default.
- W3216604328 hasAuthorship W3216604328A5090607268 @default.
- W3216604328 hasAuthorship W3216604328A5091809961 @default.
- W3216604328 hasBestOaLocation W32166043281 @default.
- W3216604328 hasConcept C121608353 @default.
- W3216604328 hasConcept C126322002 @default.
- W3216604328 hasConcept C143998085 @default.
- W3216604328 hasConcept C2776248978 @default.
- W3216604328 hasConcept C2776694085 @default.
- W3216604328 hasConcept C2778227246 @default.
- W3216604328 hasConcept C2778822529 @default.
- W3216604328 hasConcept C2989005 @default.
- W3216604328 hasConcept C3019894029 @default.
- W3216604328 hasConcept C502942594 @default.
- W3216604328 hasConcept C526805850 @default.
- W3216604328 hasConcept C71924100 @default.
- W3216604328 hasConceptScore W3216604328C121608353 @default.
- W3216604328 hasConceptScore W3216604328C126322002 @default.
- W3216604328 hasConceptScore W3216604328C143998085 @default.
- W3216604328 hasConceptScore W3216604328C2776248978 @default.
- W3216604328 hasConceptScore W3216604328C2776694085 @default.
- W3216604328 hasConceptScore W3216604328C2778227246 @default.
- W3216604328 hasConceptScore W3216604328C2778822529 @default.
- W3216604328 hasConceptScore W3216604328C2989005 @default.
- W3216604328 hasConceptScore W3216604328C3019894029 @default.
- W3216604328 hasConceptScore W3216604328C502942594 @default.
- W3216604328 hasConceptScore W3216604328C526805850 @default.
- W3216604328 hasConceptScore W3216604328C71924100 @default.
- W3216604328 hasIssue "Supplement_6" @default.
- W3216604328 hasLocation W32166043281 @default.
- W3216604328 hasOpenAccess W3216604328 @default.
- W3216604328 hasPrimaryLocation W32166043281 @default.
- W3216604328 hasRelatedWork W2083295194 @default.
- W3216604328 hasRelatedWork W2157808018 @default.
- W3216604328 hasRelatedWork W2516833820 @default.
- W3216604328 hasRelatedWork W2587851724 @default.
- W3216604328 hasRelatedWork W2789731973 @default.
- W3216604328 hasRelatedWork W2802232291 @default.
- W3216604328 hasRelatedWork W3111094672 @default.
- W3216604328 hasRelatedWork W3216604328 @default.
- W3216604328 hasRelatedWork W4253848392 @default.
- W3216604328 hasRelatedWork W3023552561 @default.
- W3216604328 hasVolume "23" @default.
- W3216604328 isParatext "false" @default.
- W3216604328 isRetracted "false" @default.
- W3216604328 magId "3216604328" @default.
- W3216604328 workType "article" @default.